Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
AnaptysBio, Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, meaning that each active application is being scrutinized by a different official. This distribution allows for independent examination paths for each of the company's 2 pending actions. This structure suggests that the applicant is pursuing multiple technical developments that are being evaluated on their own merits by different patent office personnel.
The prosecution activity is centralized within 1 distinct art unit, which ensures that all technical reviews are conducted by the same specialized group at the patent office. ROONEY, NORA MAUREEN is the busiest examiner for the portfolio, with 1 pending office action currently assigned. Because this examiner handles 1 of the 2 pending matters, they are responsible for half of the total pending workload. This arrangement requires the company to navigate the specific requirements of two different examiners who are both operating within the same administrative and technical framework, necessitating a consistent but nuanced approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260692 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR HIDRADENITIS SUPPURATIVA | ROONEY, NORA MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260692 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR HIDRADENITIS SUPPURATIVA | ROONEY, NORA MAUREEN | — |
| 18250194 | B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME | PETERS, ALEC JON | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260692 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR HIDRADENITIS SUPPURATIVA | ROONEY, NORA MAUREEN | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18250194 | B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME | PETERS, ALEC JON | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Apr 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial